Corcept Therapeutics Incorporated has announced impressive financial results for the third quarter of 2026, showcasing a significant increase in revenue and net income. The company reported a revenue of $340.5 million, marking a 64% increase compared to the same period last year. This growth is attributed to strong sales of its products, particularly Lifyorli and Korlym, as well as a broader acceptance of its treatments in the market.

Corcept, based in Redwood City, California, specializes in the development and commercialization of medications aimed at treating severe endocrinologic, oncologic, metabolic, and neurologic disorders. The company operates within the pharmaceutical preparations sector, with its stock traded on the Nasdaq under the ticker symbol CORT. Corcept has been recognized as a large accelerated filer and has consistently reported strong financial performance in its recent filings.

According to the recent 8-K filing dated November 3, 2026, Corcept's revenue for the third quarter of 2026 was driven by $249.1 million from Korlym and its authorized generic products, alongside $91.4 million from Lifyorli. The company also reiterated its revenue guidance for the year, projecting between $1.1 billion and $1.2 billion.

In terms of net income, Corcept reported $126.8 million for the third quarter, a substantial increase from $19.7 million in the same quarter of 2025. This translates to a net income per share of $1.01, significantly up from $0.16 in the previous year. The company has also seen a rise in its cash and investments, totaling $662.3 million, reflecting a $117.7 million increase from the previous quarter.

The filing highlights Corcept's ongoing commitment to clinical development, particularly in the treatment of Cushing's syndrome and ovarian cancer. The company has noted that awareness of Cushing's syndrome is increasing, which is expected to drive growth in its endocrinology business. The uptake of Lifyorli in ovarian cancer has also been rapid, with over 2,300 patients treated since its launch.

Looking ahead, Corcept is preparing for the resubmission of a New Drug Application for relacorilant, which is anticipated to be reviewed by the FDA by December 17, 2026. The company is also nearing completion of enrollment for its Phase 2 trial of relacorilant in patients with platinum-sensitive ovarian cancer, with results expected by the end of next year.

This robust financial performance and ongoing clinical developments position Corcept Therapeutics favorably in the competitive pharmaceutical landscape. As the company continues to expand its product offerings and market presence, it may influence market dynamics and attract investor interest.